• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 16, 2018

View Archived Issues

Wages of CIN seen as big, Beyondspring case made for tidy plinabulin payoff

With the first biosimilar to Neulasta (pegfilgrastim) freshly approved and data due in the fourth quarter of this year from Beyondspring Inc.'s phase III Study 105 testing plinabulin against the Amgen Inc. blockbuster, Wall Street is busy handicapping the latter in chemotherapy-induced neutropenia (CIN). Read More

Irregular flow improves bioreactor platelet production

Japanese scientists at the Center for induced Pluripotent Stem (iPS) Research and Application (CiRA) at Kyoto University have shown for the first time that small levels of turbulence in blood promote the generation of platelets. Read More

Draft legislation on Australia’s R&D tax incentive receives mixed industry response

PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said. Read More

Other news to note

Dermavant Sciences Inc., of Phoenix, a subsidiary of Roivant Sciences Ltd., said it agreed to purchase rights to tapinarof, an aryl hydrocarbon receptor modulating agent in development for psoriasis and atopic dermatitis, from London-based Glaxosmithkline plc.  Read More

Financings

Octave Bioscience Inc., of Menlo Park, Calif., said it completed a series A funding of $14 million led by BCBS Venture Partners, with participation from Echo Health Venture (a collaboration of Cambia Health Solutions and Mosaic Health Solutions), Section 32 and new as well as existing private investors.  Read More

Clinical data for July 13, 2018

Read More

Regulatory actions for July 13, 2018

Read More

Bench Press: BioWorld looks at translational medicine

To date, increases in healthspan have not kept up with those in lifespan, and many elderly, despite surviving cancer and cardiovascular disease that would have once killed them, are in poor health overall. Recent studies have suggested that senescent cells, which are not dying but have stopped dividing, are contributors to the frailty that accompanies aging. Now a team from the Mayo Clinic has put that idea to the test directly, transplanting senescent cells into young mice.  Read More

Cytodyn looks for breakout beyond HIV, picks up Prostagene

Cytodyn Inc. is seeking to expand prospects for lead program PRO-140 beyond HIV and a more recent effort in graft-vs.-host disease (GVHD) by evaluating its use in cancer and immunology. To drive that effort, the Vancouver, Wash.-based firm is bringing in Prostagene LLC, a privately held company focused on prostate cancer diagnostics and therapies seeking to prevent cancer metastasis by blocking CCR5. The companies said that research conducted by Cytodyn along with Richard Pestell, Prostagene's CEO, and his collaborators showed that selectively blocking the CCR5 receptor and the interaction of the chemokine CCL5/RANTES was important to modulate immune cell trafficking. The CCR5 receptor also is believed to play a role in cancer cell invasion and metastasis. Read More

Midyear analysis: Partnering transactions show no signs of slowing down in 2018

At the midpoint of the year, the global biopharma industry has recorded 554 partnering deals – a total that suggests that companies are still maintaining a high priority on business development through collaborations to help them execute on their business plans. The volume of partnering deals recorded by BioWorld in the second quarter, at 281, was about the same as those completed in the first quarter. However, year to date, the total number of transactions are about 10 percent down from the total recorded at this time last year. (See Volume of biopharma deals, right.) Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 17, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • Multiple myeloma and antibodies

    Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

    BioWorld
    The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe